Omalizumab

Omalizumab
Klinički podaci
AHFS/Drugs	Monografija
Identifikatori
CAS broj	242138-07-4
ATC kod	R03DX05
DrugBank	DB00043
ChEMBL	CHEMBL1201589
Hemijski podaci
Formula	C6450H9916N1714O2023S38
Mol. masa	145058,2 g/mol
Fizički podaci
Tačka topljenja	61 °C (142 °F)
Farmakokinetičkipodaci
Poluvreme eliminacije	26 dana
Izlučivanje	Renalno, bilijarno
Farmakoinformacioni podaci
Trudnoća	?
Pravni status
Način primene	Subkutano

Omalizumab(Xolair) jehumanizovano antitelokoje se koristi za redukovanje senzitivnosti na udahnute ili progutane alergene, posebno za kontrolu umerene do jake alergijskeastme,koja nije responsivna na visoke dozekortikosteroida.Omalizumab je rekombinantno DNK-izvedeno IgG1k monoklonalno antitelo, koje se selektivno vezuje za ljudskiimunoglobulin E(IgE). Xolair se proizvodi pomoću CHO ćelija.^[2]^[3]^[4]

Reference

↑Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”.Nucleic Acids Res40(Database issue): D1100-7.DOI:10.1093/nar/gkr777.PMID 21948594.edit
↑Karagiannis SN, Wang Q, East N, Burke F, Riffard S, Bracher MG, Thompson RG, Durham SR, Schwartz LB, Balkwill FR, Gould HJ: Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol. 2003 Apr;33(4):1030-40.PMID 12672069
↑Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011).„DrugBank 3.0: a comprehensive resource for omics research on drugs”.Nucleic Acids Res.39(Database issue): D1035-41.DOI:10.1093/nar/gkq1126.PMC 3013709.PMID 21059682.
↑David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008).„DrugBank: a knowledgebase for drugs, drug actions and drug targets”.Nucleic Acids Res36(Database issue): D901-6.DOI:10.1093/nar/gkm958.PMC 2238889.PMID 18048412.

Literatura

Hardman JG, Limbird LE, Gilman AG. (2001).Goodman & Gilman's The Pharmacological Basis of Therapeutics(10 izd.). New York: McGraw-Hill.DOI:10.1036/0071422803.ISBN 0-07-135469-7.
Thomas L. Lemke, David A. Williams, ur. (2007).Foye's Principles of Medicinal Chemistry(6 izd.). Baltimore: Lippincott Willams & Wilkins.ISBN 0-7817-6879-9.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

Omalizumab

[1] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”.Nucleic Acids Res40(Database issue): D1100-7.DOI:10.1093/nar/gkr777.PMID 21948594.edit

[2] Karagiannis SN, Wang Q, East N, Burke F, Riffard S, Bracher MG, Thompson RG, Durham SR, Schwartz LB, Balkwill FR, Gould HJ: Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol. 2003 Apr;33(4):1030-40.PMID 12672069

[3] Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011).„DrugBank 3.0: a comprehensive resource for omics research on drugs”.Nucleic Acids Res.39(Database issue): D1035-41.DOI:10.1093/nar/gkq1126.PMC 3013709.PMID 21059682.

[4] David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008).„DrugBank: a knowledgebase for drugs, drug actions and drug targets”.Nucleic Acids Res36(Database issue): D901-6.DOI:10.1093/nar/gkm958.PMC 2238889.PMID 18048412.

[1]

[2]

[3]

[4]